Section Arrow
NMRA.NASDAQ
- Neumora Therapeutics
(Financial Status)
Quotes are at least 15-min delayed:2025/07/16 07:58 EDT
Pre Market
Last
 1.49
+0.04 (+2.76%)
Bid
1.48
Ask
1.5
High 1.5 
Low 1.41 
Volume 5697 
Regular Hours
Last
 1.45
+0.18 (+14.17%)
Day High 
1.5 
Prev. Close
1.27 
1-M High
1.41 
Volume 
2.02M 
Bid
1.48
Ask
1.5
Day Low
1.25 
Open
1.29 
1-M Low
0.7158 
Market Cap 
205.42M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.96 
20-SMA 0.88 
50-SMA 0.8 
52-W High 17.1874 
52-W Low 0.611 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.61/-1.18
Enterprise Value
205.42M
Balance Sheet
Book Value Per Share
1.41
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KAPAKairos Pharma Ltd.1.17+0.4849+70.78%-- 
Pre Market 0.98 -0.19 -16.24%
NCNANuCana plc0.0502+0.0043+9.37%-- 
Pre Market 0.0502 0 0.00%
PLRZPolyrizon Ltd1.04+0.3579+52.47%-- 
Pre Market 1 -0.04 -3.85%
CYCCCyclacel Pharmaceuticals Inc12.33+9.02+272.51%0.08PE
Pre Market 8.51 -3.82 -30.98%
IOVAIovance Biotherapeutics1.94-0.07-3.48%-- 
Pre Market 1.91 -0.03 -1.55%
Quotes are at least 15-min delayed:2025/07/16 07:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.